Tvardi Therapeutics Inc (fra:69C) Share Price

Company Profile

Business description
Tvardi Therapeutics Inca clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting Signal Transducer and Activator of Transcription 3 (STAT3) to treat inflammatory and proliferative diseases with unmet need. Its pipeline includes two oral, small molecule STAT3 inhibitors: TTI-101 and TTI-109. TTI-101 is its first-generation direct STAT3 inhibitor, currently in Phase 1b/2 clinical development in hepatocellular carcinoma (HCC). TTI-109 is a phosphate prodrug of TTI-101 that is mechanistically identical to its parent molecule but is designed to enhance its ability to target STAT3.
Contact
3 Sugar Creek Center boulevard
Suite 525
Sugar LandTX77478
USA
T: +1 713 489-8654
https://www.tvarditherapeutics.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
12

Recommended

We see regulatory risk from both the US and Chinese governments.

Seth Goldstein, CFA | 25 October 2026

Near-term pain, long-term potential.

Dan Baker | 22 October 2026

We see the company’s momentum in its core advertising business, as well as adoption of Muse, as early signals that the firm’s AI playbook is working.

Malik Ahmed Khan, CFA | 22 October 2026

Index	Last price	Change	% Change
All Ordinaries	8,926.60	20.80	0.23%
CAC 40	7,782.82	28.44	-0.36%
DAX 40	25,181.65	190.10	-0.75%
Dow JONES (US)	52,215.16	652.82	-1.23%
FTSE 100	10,690.36	34.67	-0.32%
HKSE	23,225.29	131.92	0.57%
NASDAQ	25,955.34	53.52	-0.21%
Nikkei 225	62,549.67	143.49	-0.23%
NZX 50 Index	13,733.93	12.91	-0.09%
S&P 500	7,623.68	39.75	-0.52%
S&P/ASX 200	8,809.90	14.70	0.17%
SSE Composite Index	3,690.80	0.33	0.01%